Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Completed 29Recruiting 8Terminated 5Withdrawn 3Unknown 3No longer available 2Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Sarcoma 3Thoracic 1Other hematologic neoplasm 1Lymphoid 1

Conditions

Sarcoma 2Lung Neoplasms 1Liposarcoma, Myxoid 1Leiomyosarcoma 1

Interventions

Cyclophosphamide 9Radiotherapy 8Temozolomide 6Magnetic Resonance Spectroscopy 6Filgrastim 6Doxorubicin 6pazopanib 5Gemcitabine 5pembrolizumab 4Vincristine 4Radiation 4Etoposide 4Docetaxel 4Carboplatin 4Biopsy 4Trabectedin 3Taxes 3Specimen Handling 3Paclitaxel 3Nivolumab 3Irinotecan 3Drug Therapy 3olaparib 2niraparib 2liposomal doxorubicin 2fludarabine phosphate 2fludarabine 2brigimadlin 2Trastuzumab 2Surgical Procedures, Operative 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Withdrawn × Trabectedin × Sarcoma × Clear all
NCT03397186 2019-09-10

Immune Changes Following Trabectedin in Patients With Metastatic or Unresectable Sarcoma

Fred Hutchinson Cancer Center

Phase 2 Withdrawn
Sarcoma

Sarcoma, Liposarcoma, Myxoid

NCT03437070 2019-03-18

Trabectedin, Doxorubicin and Olaratumab in Patients With Metastatic or Recurrent Leiomyosarcoma

University of Miami

Phase 1 Withdrawn
Sarcoma

Leiomyosarcoma

NCT03496519 2018-10-09

Assessing the Combination of Durvalumab (MEDI4736) and Trabectedin in Solid Tumors

University of Colorado, Denver

Phase 1 Withdrawn
SarcomaThoracic

Lung Neoplasms, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡